Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sulfisoxazole
Drug ID BADD_D02636
Description A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.
Indications and Usage For the treatment of severe, repeated, or long-lasting urinary tract infections, meningococcal meningitis, acute otitis media, trachoma, inclusion conjunctivitis, nocardiosis, chancroid, toxoplasmosis, malaria and other bacterial infections.
Marketing Status approved; vet_approved
ATC Code J01EB05; S01AB02
DrugBank ID DB00263
KEGG ID D00450
MeSH ID D013444
PubChem ID 5344
TTD Drug ID D09TBD
NDC Product Code Not Available
UNII 740T4C525W
Synonyms Sulfisoxazole | Sulfasoxizole | Sulfadimethyloxazole | Sulfafurazole | Sulfafurazol FNA | Sulfisoxazole Diolamine | Diolamine, Sulfisoxazole | Sulfisoxazole, Ammonium Salt | Ammonium Salt Sulfisoxazole | Sulfisoxazole, Monolithium Salt | Monolithium Salt Sulfisoxazole | V-Sul | V Sul | Sulfisoxazole, Monosodium, Monomesylate Salt | Sulfisoxazole, Triammonium Salt | Triammonium Salt Sulfisoxazole | Gantrisin | Gantrisin Pediatric | Pediatric, Gantrisin | TL-azole | TL azole | Neoxazoi | Sulfisoxazole, Monosodium Salt | Monosodium Salt Sulfisoxazole
Chemical Information
Molecular Formula C11H13N3O3S
CAS Registry Number 127-69-5
SMILES CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agranulocytosis01.02.03.001--Not Available
Angioedema23.04.01.001; 10.01.05.009; 22.04.02.008--Not Available
Dermatitis23.03.04.002--Not Available
Dermatitis allergic23.03.04.003; 10.01.03.014--Not Available
Dermatitis atopic23.03.04.016; 10.01.04.004--Not Available
Drug interaction08.06.03.001--Not Available
Dyspepsia07.01.02.001--
Eczema23.03.04.006--
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Erythema nodosum23.07.02.001; 10.02.01.020--Not Available
Face oedema10.01.05.002; 08.01.07.003; 23.04.01.004--
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.006--
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Leukopenia01.02.02.001--Not Available
Mouth ulceration07.05.06.004--Not Available
Myalgia15.05.02.001--
Nausea07.01.07.001--
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema mouth23.04.01.008; 10.01.05.006; 07.05.04.001--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Periorbital oedema23.04.01.002; 10.01.05.010; 06.08.03.017--
Photosensitivity reaction23.03.09.003--
Pruritus23.03.12.001--
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages